Xylazine-BSA Conjugate

• Description :

  Xylazine is a potent alpha-2 adrenergic agonist that was initially developed as a veterinary sedative and analgesic medication. Xylazine was not approved for human use and has been increasingly found in samples of illicit drugs like fentanyl. The increase in the detection of xylazine mixed with fentanyl has corresponded with an increase in overdose deaths. In 2023, fentanyl mixed with xylazine was declared an emerging threat by the White House?s Office of National Drug Control Policy.

• Clonality :

  Monoclonal

• Purification :

  Purity: >=90%

• Components :

  Concentration: 5.0 mg/mL Formulation: Formulated in 0.015 M phosphate buffered saline (0.15M NaCl) and contains 0.05% sodium azide.

• Storage Conditions :

  2-8°C Wet Ice